Hemogenyx Pharmaceuticals Highlights Clinical Advancements and Financial Resilience in 2024

 

Hemogenyx Pharmaceuticals Plc (LSE:HEMO) has released its final results for the year ending December 31, 2024, showcasing strong clinical progress and solid financial footing. Key achievements include the launch of Phase I clinical trials for its HG-CT-1 CAR-T cell therapy, securing over £5 million in new funding, and expanding its clinical operations through strategic partnerships. These milestones position Hemogenyx as a rising force in the biopharmaceutical sector, demonstrating resilience despite broader market challenges.

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals Plc is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for blood diseases. The company is particularly focused on CAR-T cell therapies for acute myeloid leukemia and is advancing its proprietary Chimeric Bait Receptor platform, aimed at antiviral and biodefense applications.

• Year-to-Date Price Movement: -54.75%

• Average Daily Trading Volume: 37,092 shares

• Technical Sentiment Rating: Buy

• Current Market Capitalization: £7.5 million

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Ltd. ADVFN Ltd does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.

Comments are closed

WHAT IS ADVFN?

ADVFN covers all things stock market.

From the news and opinion pieces on pages like this to share discussion forums, charting tools, financials, live share prices and Level 2, order book data

If you trade or invest ADVFN has the tools you need to make the right decisions.

• 

  101 Ways to Pick Stock Market Winners

  You need the number one bestselling investment guide, the definitive text for day traders, investors and stock pickers.

• 

  The Death of Wealth

  Dissecting the global economy and the financial markets, the book lays out the evidence for the next economic game changer: the Death of Wealth.

• 

  Beth Anne Lamar

• 

  John Williams

• 

  Jekyll & Hyde

• 

  Brokermandaniel